Abstract
AF 3013, the active metabolite of prulifloxacin, was tested to determine its inhibitory and bactericidal activities against 396 nosocomial and 258 community Italian isolates. Compared with that of ciprofloxacin, its activity (assessed in MIC and minimal bactericidal concentration tests) was generally similar or greater against gram-positive bacteria and greater against gram-negative bacteria. In time-kill assays using selected isolates, its bactericidal activity was comparable to that of ciprofloxacin.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Infective Agents / pharmacology*
-
Community-Acquired Infections / microbiology*
-
Cross Infection / microbiology*
-
Dioxolanes / pharmacology*
-
Fluoroquinolones*
-
Gram-Negative Bacteria / drug effects*
-
Gram-Positive Bacteria / drug effects*
-
Humans
-
Italy
-
Microbial Sensitivity Tests
-
Piperazines / pharmacology*
-
Quinolones / pharmacology*
Substances
-
AF 3013
-
Anti-Infective Agents
-
Dioxolanes
-
Fluoroquinolones
-
Piperazines
-
Quinolones
-
prulifloxacin